OpenAI says GPT-Rosalind offers new leads for neurodegenerative disease drug discovery
On October 21, 2026, OpenAI said that GPT-Rosalind proposed new leads in drug discovery: after the DCTN1 gene associated with Perry syndrome was disrupted, the expression of genes related to cholesterol synthesis increased in mouse brain data, and the model inferred from this that cholesterol may not reach the locations neurons require. OpenAI said that, in collaboration with Perturb Bio and Scripps Research, thousands of GPT-Rosalind agents worked in parallel to link gene expression results from millions of mouse brain cells with scientific literature within 32 minutes, and said it is expanding this collaboration to find new drug targets. Other reports said that the work aggregated the reports of individual agents into a public reasoning graph, and that a companion preprint was released on bioRxiv on October 16, 2026, and has not yet undergone peer review.
On October 21, 2026, OpenAI said that GPT-Rosalind proposed new leads in drug discovery: after the DCTN1 gene associated with Perry syndrome was disrupted, the expression of genes related to cholesterol synthesis increased in mouse brain data, and the model inferred from this that cholesterol may not reach the locations neurons require. OpenAI said that, in collaboration with Perturb Bio and Scripps Research, thousands of GPT-Rosalind agents worked in parallel to link gene expression results fro
Matched fieldsTitle